Gilead Sciences Inc said on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment remdesivir.
from Zee News :World https://ift.tt/2SWj4S4
from Zee News :World https://ift.tt/2SWj4S4
